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A class of drugs that effectively lowers plasma TG are the fibrates. Reduction in plasma TG by fibrate treatment depends on baseline TG levels but can reach 40% (15) . Fibrates also raise plasma levels of HDL-cholesterol, making it an attractive drug for the treatment of diabetic dyslipidemia, which is characterized by elevated TG and low HDL levels. Overall results of clinical trials, however, are mixed and not overwhelmingly in support of a broad application of fibrates to correct dyslipidemia and lower risk of coronary heart disease. The decrease in plasma TG by fibrates has been attributed to inhibition of synthesis and secretion of TG by the liver and stimulation of degradation of TG-rich lipoproteins (29, 56) . Fibrates stimulate a large panel of genes involved in hepatic mitochondrial and peroxisomal fatty acid oxidation and lipoprotein metabolism by direct high-affinity binding and consequent activation of peroxisome proliferator-activated receptor alpha (PPAR␣) (13, 27, 29, 44, 56) , thus serving as a direct pharmacological ligand of PPAR␣. PPAR␣ is a transcription factor abundant in liver that mediates the adaptive response to fasting.
Besides via pharmacological approach, plasma TG can be effectively lowered via nutritional intervention in the form of fatty fish or fish oil. Fish oil, rich in eicosapentaenoic acid (EPA, C20:5n-3) and docosahexaenoic acid (DHA, C22:6n-3), has long been considered as potential treatment to lower risk of coronary heart disease (12, 18, 19, 38) . Similar to fibrates, fatty acids present in fish oil induce hepatic expression of numerous genes via activation of PPAR␣ (51) . In addition, EPA and DHA suppress activity of the prolipogenic transcription factor sterol regulatory element binding protein-1 (SREBP-1) by inhibiting proteolytic processing of SREBP-1, a process required to generate the active mature SREBP-1 protein (24, 25) . While fenofibrate and fish oil thus both lower plasma TG and can activate the same transcription factor, a comparative analysis of the effects of fenofibrate and fish oil at transcriptome and metabolome level has yet to be performed. Therefore, to gain further insight into mechanisms underlying the effects of fenofibrate and fish oil on cardiovascular risk factors and to investigate whether these mechanisms are shared between fenofibrate and fish oil, we performed hepatic transcriptional profiling and plasma metabolite profiling in mice treated with fenofibrate or fish oil for 2 wk. Inasmuch as fenofibrate and fish oil are already known to both stimulate PPAR␣-dependent gene regulation, the focus of the analysis was on genes and pathways uniquely regulated by either fenofibrate or fish oil.
cage in a light-and-temperature controlled facility (lights on 6:30 to 18:30, 21°C) and acclimated them for 3 wk. The mice were randomized by weight-matching into three groups (n ϭ 10 in control group and n ϭ 12 in fenofibrate or fish oil intervention group) and fed a research diet (no. D10012M, Research Diets, NJ; Supplementary  Table S1 ) supplemented with sunflower oil (containing 81.3% oleic acid, 7% energy intake) in control group, sunflower oil (7% energy intake) and fenofibrate (0.03% wt/wt) in fenofibrate group, and fish oil (Marinol C-38 fish oil: 23.1% EPA and 21.1% DHA, 7% energy intake) in fish oil group for 2 wk. 1 Mice received fresh diet every 3rd day, and food consumption rate and body weight gain were monitored. At the end of treatment, mice were fasted from 7:00 to 13:00 with drinking water available and were subsequently killed by cervical dislocation under isoflurane anesthesia. Blood was collected via orbital puncture. Livers were dissected, directly frozen in liquid nitrogen and stored at Ϫ80°C until further analysis. Blood was centrifuged (4,000 g for 10 min at 4°C), and plasma was stored at Ϫ80°C. The animal experiments were approved by the animal ethics committee of Wageningen University.
Affymetrix GeneChip microarray analysis. Total RNA was prepared from mouse livers using TRIzol reagent (Invitrogen, Breda, The Netherlands), treated with DNase, and purified on columns using the RNeasy Mini Kit (Qiagen, Venlo, The Netherlands) following the supplier's protocol. RNA concentrations were measured by absorbency at 260 nm, and the quality and integrity were verified with the RNA 6000 Nano assay on the Agilent 2100 Bioanalyzer (Agilent Technologies, Amsterdam, the Netherlands) according to the manufacturer's instructions. Microarray analysis was performed on individual mouse livers. Five micrograms of RNA were labeled using the Affymetrix One-Cycle Target Labeling Assay kit (Affymetrix, Santa Clara, CA). Hybridization, washing, and scanning of Affymetrix Mouse Genome 430 2.0 Arrays were done according to standard Affymetrix protocols. Scans of the Affymetrix arrays were processed using packages from the Bioconductor project (16) . Raw signal intensities were normalized by using the GCRMA algorithm (69) . Probe-sets were defined according to Dai et al. (10) using remapped chip definition file (CDF) version 11.0.2 based on the Entrez gene database. The Affymetrix Mouse Genome 430 2.0 Arrays target 16,331 unique genes based on this CDF. Genes were filtered on expression value Ͼ20 in five samples, resulting in a set of 7,400 expressed genes. The Bioconductor R package Linear models for microarray data (LIMMA) was used to identify differentially expressed genes. To balance between unspecific responses from the two treatments and relative weak transcriptional effects by fish oil, the genes that met the cut-off of mean absolute fold change Ͼ1.2 and false discovery rate corrected q-value Ͻ0.05 (55) were considered to be significantly regulated. Among the significantly regulated genes, only those that are associated with a canonical pathway in the Ingenuity Pathway Knowledge Base were considered for Ingenuity Pathway Analysis (IPA; Ingenuity Systems, Redwood City, CA). In addition, all genes represented on the array were also considered for the unbiased Gene Set Enrichment Analysis (GSEA) (58) . This analysis was run using 1,000 permutations per gene set. All microarray data are MIAME compliant and have been submitted to the Gene Expression Omnibus (accession number GSE 32706).
Lipidomic and metabolic profiling. The liquid chromatographymass spectrometry (LC-MS) methods for measuring plasma lipids and nonesterified free fatty acids (NEFAs) and the gas chromatography (GC)-MS method for measuring a broad range of metabolites were identical to the methods reported by Wopereis et al. (68) . The samples were analyzed in randomized order. Data for each sample were corrected for the recovery of the internal standard for injection. The performance of the methods was carefully monitored by using multiple internal standards (5-10 depending on the method, including analogs and 2H-and 13C-labeled metabolites) as described previously (68) . Furthermore, a quality control sample prepared by pooling of plasma from all samples was analyzed after every 10th study sample. Batches were only accepted if the relative standard deviation (RSD) of the peak area ratio for all internal standards was Ͻ20%. Metabolites were only accepted if the RSD was Ͻ20%, unless large differences between treatment groups were observed. Batch to batch differences in data were removed by synchronizing medians of quality control samples per batch. Metabolites were annotated by using an in-house metabolite database containing retention time information, MS spectra (electron impact ionization for GC-MS data), MS/MS spectra (LC-MS), and accurate mass data (LC-MS) of reference substances. The confidence of identification was 100% unless indicated otherwise. Accurate MS and MS/MS data of reference substances and metabolites in the study samples were acquired by using Thermo LTQ-FT and Thermo LTQ-Orbitrap instruments (Thermo Fisher Scientific, Waltham, MA). Finally, the LC-MS NEFA dataset contained 22 free fatty acids; the LC-MS lipid dataset contained 184 lipid metabolites; and the GC-MS dataset contained 137 metabolites. Also, 41 different metabolite ratios and sums were calculated. Detailed information on these metabolites could be acquired upon request.
Statistical analysis. Results are reported as means Ϯ SE. The comparison of different groups was carried out using ANOVA and unpaired two-tailed Student's t-test. The Kruskal-Wallis test or MannWhitney U-test was used if groups did not show equal variance. Spearman rank correlation was used to correlate hepatic gene expression signals with plasma metabolite levels. Differences were considered statistically significant when P Ͻ 0.05.
RESULTS
Changes in liver and body weight and selected plasma metabolites. Mice received fenofibrate (0.03% wt/wt) or fish oil (3% wt/wt) in their feed for 2 wk. Neither fenofibrate nor fish oil influenced food intake ( Table 1) . Fish oil but not fenofibrate significantly increased bodyweight (ϩ6.2% vs. ϩ2.7%), while fenofibrate but not fish oil increased liver weight (ϩ1.8% vs. Ϫ0.1%, respectively). Fenofibrate raised plasma total cholesterol (ϩ29.9%), whereas fish oil had the opposite effect (Ϫ32.8%). Both fenofibrate and fish oil reduced plasma triglycerides although the effect of fenofibrate was more pronounced (Ϫ49.1% vs. Ϫ21.8%). Consistent with stimulation of hepatic fatty acid oxidation, fenofibrate markedly raised plasma ketone bodies (ϩ316%). A similar effect was observed for ribose. Interestingly, fish oil significantly reduced plasma levels of phospholipids (Ϫ42.3% for combined phosphatidylcholine and phosphatidylethanolamine), lysophospholipids (Ϫ28.0% for combined lysophosphatidylcholine and lysophosphatidylethanolamine), and sphingomyelins (Ϫ19.4%), which was not observed for fenofibrate.
Fenofibrate reduced plasma total NEFA levels (Ϫ18.8%), with its effect equally distributed among the various fatty acid classes (SFA, MUFA, PUFA). Fish oil lowered total plasma NEFA to a similar extent as fenofibrate but its effect across the various fatty acid classes was different. Fish oil decreased levels of all n-6 and n-9 long-chain fatty acids and, as expected, increased plasma levels of n-3 PUFA levels ( Table 2 ). The stronger reduction in MUFA by fish oil compared with fenofibrate was mainly attributable to reduced levels of C18:1 fatty acids and presumably due to lower content of oleic acid in the feed of fish oil treated mice (Table 2 and  Supplementary Table S1 ).
Fenofibrate and fish oil treatments lead to PPAR␣ activation. Since fenofibrate and EPA/DHA are known ligands of PPAR␣,
we determined to what extent PPAR␣ was activated by the two treatments. Fenofibrate and fish oil caused upregulation of many genes involved in PPAR␣-dependent pathways such as hepatic fatty acid uptake (Fig. 1A) , mitochondrial fatty acid ␤-oxidation (Fig. 1B) , peroxisomal fatty acid ␤-oxidation (Fig.  1C) , microsomal fatty acid -hydroxylation (Fig. 1D ), and ketogenesis ( Fig. 1E ), including many classical PPAR␣ target genes (50) . Consistent with fenofibrate being a higher affinity PPAR␣ agonist compared with EPA/DHA, more pronounced inductions were observed in fenofibrate treated mice. These data demonstrate that fenofibrate and fish oil treatment led to activation of PPAR␣, in line with published data (36). Data are expressed as means Ϯ SE. PC, phosphatidylcholine; LPC, lysophosphatidylcholine; LPE, lysophosphatidylethanolamine; PE, phosphatidylethanolamine; SM, sphingomyelin. †LCMS platform, n ϭ 10, 12, and 12 for control, fenofibrate, and fish oil group, respectively; arbitrary units used. ‡GCMS platform, n ϭ 9, 12, and 11 for control, fenofibrate, and fish oil group, respectively; arbitrary units used. §Triacylglycerol assayed with the glycerol based kit; and glucose assayed with glucose oxidization based kit. *P Ͻ 0.05, **P Ͻ 0.01, ***P Ͻ 0.001 vs. control. Comparative analysis of gene regulation by fenofibrate and fish oil. Dendrogram of hierarchical clustering of the various mice based on the complete liver transcriptome showed that fenofibrate-treated mice formed a highly distinct group from fish oil-treated and control mice, illustrating the much more pronounced effects of fenofibrate on hepatic gene expression compared with fish oil (Fig. 2) . Furthermore, since the three groups clustered separately, the analysis indicated that the variability in gene expression within the three groups was much less compared with the variability between the groups. To compare the whole hepatic genome effects of fenofibrate and fish oil, we carried out scatter plot analysis (Fig. 3) . The similarity in gene regulation between fenofibrate-and fish oil-treated mice was relatively small and was mainly observed with respect to upregulation of gene expression. Fold inductions of gene expression were generally higher in fenofibratecompared with fish oil-treated mice. Interestingly, some genes strongly upregulated by fenofibrate were downregulated by fish oil, including Ly6d, Cidec, Pdk4, Defb1, Ucp2, Cidea, and Pltp. Other genes were upregulated by fish oil but not by fenofibrate, including Mt2, Derl3, and Agxt2l1, or even strongly downregulated by fenofibrate, such as Clec2h, Aox3, Cyp2c37, and Hsd3b5 (Fig. 3) . As fenofibrate and fish oil both activate PPAR␣, differential hepatic gene regulation by fish oil compared with fenofibrate suggest another type of regulatory mechanism by fish oil treatment not involving PPAR␣.
Pathway analysis of microarray data. To gain insight into pathways uniquely regulated by fenofibrate and fish oil, GSEA was performed. Partial overlap in the upregulated gene sets was observed between fenofibrate and fish oil, mostly covering various aspects of fatty acid metabolism (Fig. 4) . Many gene sets were specifically induced by fenofibrate, including electron transport chain and TCA cycle (Fig. 4A) . Also, a small number of gene sets was upregulated by fenofibrate but decreased by fish oil, including lipogenesis, glycolysis, and gluconeogenesis, and the pentose phosphate pathway. Interestingly, autophagy, ABC transporters, and arachidonic acid metabolism were specifically induced by fish oil (Fig. 4B) . In terms of downregulation, blood clotting cascades, complement cascades, and antigen processing and presentation were commonly regulated by fenofibrate and fish oil. Gene sets that were exclusively downregulated by fish oil included lipoprotein metabolism, cholesterol synthesis and esterification, and prostaglandin synthesis regulation. Taken together, several pathways specifically regulated by either fenofibrate or fish oil could be identified. Expectedly, most of the common regulation by fenofibrate and fish oil relates to PPAR␣-dependent gene sets connected to fatty acid catabolism.
One of the gene sets specifically induced by fenofibrate corresponded to TCA cycle. In agreement with this finding, fenofibrate but not fish oil significantly raised plasma levels of several TCA cycle intermediates, including isocitrate, ␣-ketoglutarate, succinate, fumarate, and malate (Table 3 ). In accordance with altered hepatic amino acid metabolic pathways upon fenofibrate and fish oil treatment, significant changes in plasma amino acids levels were observed in both treatment groups (Supplementary Table S3 ). Most assayed amino acids were increased by fenofibrate, including glutamate, glycine, isoleucine, leucine, phenylalanine, serine, tryptophan, tyrosine, and valine, whereas only glycine was increased by fish oil (Supplementary Table S3 ). These data correspond well with downregulation of genes involved in urea cycle and metabolism of amino groups in fenofibrate treated mice (Fig. 4A) (Supplementary Table S2) .
Genes specifically regulated by fenofibrate or fish oil treatment. Venn diagrams were created to identify genes that were specifically regulated by fenofibrate or fish oil treatment (Fig. 5, A and  B) . Most genes upregulated or downregulated by fish oil were similarly regulated by fenofibrate. To better characterize fenofi- brate-and fish oil-specific gene regulation, we compiled the top 40 of genes specifically upregulated (Fig. 5, C and D) and downregulated (Fig. 5 , E and F) by fenofibrate and fish oil, respectively, and ranked according to fold change. Changes in gene expression by fish oil and fenofibrate are shown in parallel.
A relatively large proportion of top 40 genes specifically upregulated by fenofibrate were known PPAR␣ target genes (50) . In contrast to the classical PPAR␣ target genes involved in fatty acid catabolism shown in Fig. 1 , these genes, which included Cidec, Pdk4, Ucp2, Cidea, Pltp, Abcd2, Me1, and Fabp4, were downregulated by fish oil (Fig. 5C ). Among the top 40 genes specifically downregulated by fenofibrate treatment, several genes are involved in complement cascade (C8b, C6, and C9), coagulation cascade (Serpine2 and F11) and general inflammatory regulation and response (Orm2, Bcl6, Saa1, Saa2, Ifit1, Il6ra, Il1r1, and Irf5) (Fig. 5E) , which is consistent with the strongly downregulated acute phase response signaling (IPA, data not shown), complement cascade and coagulation cascade in fenofibrate treated mice (Fig. 4A and Supplementary Table S2 ). Also, a number of fenofibratespecific genes were related to steroid metabolism, which fits with reduction in androgen and estrogen metabolism as indicated by GSEA (Fig. 4A) . With respect to fish oil treatment, several of the top 40 genes specifically upregulated by fish oil are involved in amino acid metabolism (Agxt2l1, Aox3, Clpx, Cyp7b1, and Aadat) and arachidonic acid metabolism (Cyp2c37, Cyp2c44, and Cyp2j9) (Fig. 5D) . Most of them were downregulated by fenofibrate, suggesting that the underlying mechanism of regulation is fish oil specific and not PPAR␣ related. Among the top 40 genes specifically downregulated by fish oil, a marked enrichment of SREBP target genes was apparent (21, 43) (Fig. 5F and Supplementary Table S2), which is consistent with the observed downregulation in both cholesterol and fatty acid biosynthetic pathways (Fig. 4B) . Strikingly, expression of several SREBP1 targets involved in lipogenesis (Fasn, Elovl6, Fads2, and Fads1) was upregulated by fenofibrate, but down- regulated by fish oil (Fig. 5F ). The hepatic down-and upregulation of SREBP1 target stearoyl-CoA desaturase (Scd1, Supplementary Table S2 ) by fish oil and fenofibrate was substantiated by corresponding changes in plasma ⌬9-desaturation indexes (stearoyl-CoA desaturase activity) ( Table 4 ).
The precise molecular mechanism behind the plasma TG lowering effect of fish oil remains controversial. To gain insight into potential mechanisms, we determined which genes showed the highest correlation with plasma TG levels in the combined control and fish oil-treated mice (Fig. 6A) . Remarkably, many genes showing a highly significant negative correlation with plasma TG were PPAR␣ target genes involved in fatty acid metabolism. In comparison, lipogenic and cholesterol biosynthetic genes, despite being strongly downregulated by fish oil, showed weaker correlation with plasma TG. Similar observations were made for correlations of gene expressions with plasma cholesterol levels and phosphatidylcholine (Fig.  6A) . IPA on genes showing the highest positive or negative correlation with plasma TG, cholesterol, and phosphatidylcholine identified "fatty acid metabolism," a PPAR␣ regulated pathway, as the most significant pathway (data not shown). Pathways related to fatty acid or cholesterol biosynthesis were much less significant. Specific examples of genes showing a highly significant correlation with plasma TG, cholesterol, or lysophosphatidylcholine are shown in Fig. 6B . These results may imply that the effects of fish oil on various plasma lipids may occur via changes in fatty acid oxidation via activation of PPAR␣, and to a lesser extent via suppression of fatty acid and cholesterol biosynthesis, which are under control of SREBP.
DISCUSSION
Using a combination of transcriptional and plasma metabolite profiling, we carried out a comprehensive comparison of the effects of fenofibrate and fish oil treatment in mice. Due to the treatment duration, some of the observed changes in gene expression changes will be secondary to metabolic perturbations elicited by the treatment, although a major portion of gene expression changes likely reflects direct regulation. Both fenofibrate and fish oil induced numerous genes involved in hepatic fatty acid catabolism and other PPAR␣-dependent pathways. Fenofibrate consistently caused higher fold-inductions, in agreement with fenofibrate being a better PPAR␣ agonist compared with EPA and DHA (51) . In contrast to fish oil, fenofibrate caused hepatomegaly and raised plasma ketone bodies, which are known PPAR␣-dependent effects. The data thus indicate that compared with fenofibrate, fish oil treatment leads to modest activation of PPAR␣ in liver. However, while effects of fenofibrate are almost entirely mediated by PPAR␣, fish oil additionally acts upon other regulatory pathways to exert multiple effects, reflecting a property characteristic of nutrients.
Consumption of fish oil lowers circulating TG in humans (19) , which could be reproduced in mice. Fish oil fatty acids may stimulate postendoplasmic reticulum (post-ER) presecretory proteolysis of ApoB via a mechanism dependent on fatty acid peroxidation, leading to reduced TG secretion by hepatocytes (47) . Alternatively, lowering of circulating TG may occur via the observed downregulation of fatty acid synthesis. In addition, a number of other mechanisms has been proposed, including activation of PPAR␥ in adipose tissue (12, 18) . Conflicting data exist on whether lowering of plasma TG and cholesterol by fish oil is dependent on PPAR␣ (11, 59) . We observed pronounced enrichment for PPAR␣ targets and genes involved in fatty acid metabolism among genes showing the most significant negative correlation with plasma TG, cholesterol, and phospholipids. In comparison, lipogenic and cholesterol biosynthetic genes showed good correlation with plasma phospholipids but weaker correlation with plasma TG and cholesterol. Our results may suggest that the effect of fish oil on plasma TG and cholesterol primarily occurs via activation of PPAR␣, whereas the effect on plasma phospholipids seems to rely proportionally more on suppression of SREBP-dependent regulation of lipogenesis and cholesterol metabolism.
In contrast to earlier studies in rats but in line with the effect in humans (13) , fenofibrate increased plasma cholesterol, which in mice is almost exclusively carried in HDL. The reason for the discrepancy with previous rat studies is unclear (42, 57) . Besides via changes in apoAI expression, which was slightly but significantly reduced by both fenofibrate and fish oil, the HDL-raising effect of fenofibrate in humans may be mediated via changes in Pltp expression and activity (33, 66) . Alternatively, fenofibrate may raise plasma cholesterol levels in mice by downregulating Scarb1 (SR-BI), which was confirmed in our study (35) .
In line with numerous papers, fish oil downregulated expression of numerous SREBP target genes involved in fatty acid and cholesterol synthesis (24, 25, 59, 60) . Although SREBP1 and SREBP2 have both been suggested to be inhibited by PUFAs, data implicating SREBP1 in downregulation of gene expression by PUFAs are much more plentiful. Recently, the target of PUFAs was identified as Ubxd8, an ER membranebound protein that facilitates the degradation of Insig-1, thereby promoting proteolytic processing and activation of SREBP-1 (30) . It was shown that PUFAs inhibit the activity of Ubxd8 (30) . Hence, downregulation of hepatic fatty acid and cholesterol biosynthetic genes by fish oil may occur via inhibition of Ubxd8.
While several classical PPAR␣ targets involved in fatty acid oxidation were upregulated by both fenofibrate and fish oil, other established PPAR␣ targets were induced only by fenofibrate, including Cidec, Cidea, Pdk4, Ucp2, Pltp, Abcd2, Me1, and Fabp4. With the exception of Abcd2, none of these genes are involved in fatty acid oxidation but instead participate in other (lipid) metabolic pathways. Interestingly, malic enzyme (Me1) is controlled by both PPAR␣ and SREBP, as are Ucp2 (37, 50) , Fads1, Fads2, Scd1, Acsl3, Acsl4, and Acsl5 (21, 50), Abcd2 (50, 67) , and Fabp4 (26, 50) . Similarly, the PPAR␣ targets Pltp and lipid droplet-associated protein Cidea were shown to be regulated by SREBP1 (43, 64) . Thus, it is possible that the above gene set is induced by fish oil via PPAR␣ but that the effect is counterbalanced by suppression of SREBPmediated transcriptional regulation. These data indicate that responsiveness to synthetic PPAR␣ agonist may not always properly predict regulation by dietary PPAR␣ agonists, as the latter act via multiple mechanistic pathways that may converge on a single gene.
Data abound indicating that fish oil fatty acid and fibrates stimulate hepatic fatty acid uptake and catabolism (5) , which likely explains the reduced plasma NEFA levels in fenofibrate and fish oil treated mice. Although fish oil caused much weaker Data are expressed as means Ϯ SE. All organic acids were measured in the GC-MS platform, arbitrary units used. *P Ͻ 0.05, **P Ͻ 0.01, ***P Ͻ 0.001 vs. control.
induction of genes involved in fatty acid catabolic pathways compared with fenofibrate, the reduction in plasma NEFA was identical between the treatments. Fish oil may reduce plasma NEFA levels and increase weight gain by attenuating fatty acid release from adipose tissues (18, 23, 45, 48) , perhaps via activation of PPAR␥. EPA and DHA present in fish oil are endogenous PPAR␥ ligands (9, 12, 61) , and fish oil has been shown to upregulate PPAR␥ and its responsive genes in epididymal adipose tissue (8, 9, 17, 22, 39, 61) . Fish oil may thus mimic the stimulatory effect of synthetic PPAR␥ agonists on fatty acid trapping (9, 12, 61) , and weight gain (3). Since we did not collect adipose tissue, it is impossible to determine whether fish oil induced PPAR␥ target genes in adipose tissue and whether it increased adipose tissue mass.
Remarkably, pathways relevant to blood coagulation and fibrinolysis were strongly downregulated by fenofibrate and Genes were included if mean fold-change (MFC) by fenofibrate or fish oil exceeded the value of 1.2 and Bayesian corrected q was Ͻ0.05. C: top 40 genes most strongly upregulated (based on MFC) by fenofibrate but not fish oil. Known PPAR␣ target genes upregulated by fish oil by Ͼ1.2-fold yet for which the effect failed to meet statistical significance due to large variation were removed to exclusively highlight fenofibratespecific genes (Mogat1, Acot3, Cd36, Cpt1b, Slc16a13, Acot4, Crat, and Slc27a4). D: top 40 genes most strongly upregulated by fish oil but not fenofibrate. E: top 40 genes most strongly downregulated by fenofibrate but not fish oil. F: top 40 genes most strongly downregulated by fish oil but not fenofibrate. Expression levels in the control mice (Con) were set at 1 (black), and expression levels in 2 treated groups were calculated relative to the control group. The list was sorted based on fold-change of fenofibrate (Fen: C and E)-or fish oil (Fish: D and F)-treated mice. fish oil. Individual genes within these pathways were consistently downregulated by fenofibrate and fish oil, although the effect of fenofibrate was much more pronounced (Supplementary Table S2 ). Suppression of hepatic expression of these genes upon pharmacological PPAR␣ activation has been reported in rats and monkeys (6, 28) and was shown to be PPAR␣ dependent for fibrinogen ␣-, ␤-, and ␥-chain (28). In humans, fibrates reduce plasma fibrinogen levels by 12-25% (65, 70) . Recently, several genes in this pathway were found to be downregulated in human hepatocytes by synthetic PPAR␣ agonist (49) .
A weak hypocoagulant effect of fish oil has been observed in studies in humans and is likely mediated by suppression of clotting factors. Fish oil was shown to decrease hepatic transcription of kallikrein B, fibrinogen ␤-chain, antithrombin III, and protein C genes (60, 63) and lower blood fibrinogen, factors II, V, VII, and X, antithrombin III, and protein C levels in rodents (2, 32, 40, 41, 63) . Reduced activity of factor V, VII, Data are expressed as means Ϯ SE. ⌬9-Desaturation indexes were calculated from the ratios between C16:1(n-7) and C16:0, C18:1(n-7/n-9) and C18:0, and C20:1(n-9) and C20:0, respectively, in the plasma lysophosphatidylcholines. All lysophosphatidylcholine (LPC) were measured in the LC-MS platform, arbitrary units used. *P Ͻ 0.05, **P Ͻ 0.01, ***P Ͻ 0.001 vs. control. Fig. 6 . Correlation analysis between plasma metabolites and hepatic gene expression signals in control and fish oil-treated mice. Spearman rank correlation analyses were conducted between plasma metabolites and hepatic gene expression signals for those genes that were statistically significant regulated after fish oil treatment (q Ͻ 0.05). A: the respective top 20 positive (pos, r Ͼ 0.77) and negative (neg, r Ͻ Ϫ0.81) correlated genes with plasma triglyceride (TG), cholesterol, lysophosphatidylcholine (LPC), and phosphatidylcholine levels. The genes are either PPAR␣ regulated and involved in fatty acid metabolism (neg side, in circle), or SREBP regulated and involved in lipogenesis and cholesterol biosynthesis (pos side, in square). B: scatter-plots between plasma TG, cholesterol, and lysophosphatidylcholine (LPC) levels and hepatic expression level of top correlated genes. AU, arbitrary units. VIII, IX, X, XI, and XII and protein C (20, 34) and reduced plasma levels of fibrinogen, factor V, VII, and X, protein C, antithrombin III, plasminogen activator inhibitor, and ␣2 antiplasmin were also observed in human fish oil intervention studies (4, 20, 34, 46, 54, 62) . The striking parallel downregulation of blood coagulation and fibrinolysis pathways by fenofibrate and fish oil suggest they occur via a common mediator, e.g., PPAR␣.
Interestingly, consistent with previous data showing enhanced TCA cycle flux (53) and increased TCA cycle enzymes (31) by synthetic PPAR␣ ligand, plasma levels of all TCA cycle intermediates was induced by fenofibrate, perhaps as a result of enhanced amino acid degradation by fenofibrate, as revealed by GSEA.
In conclusion, the transcriptomic and metabolomic effects of fish oil and fenofibrate reflect the highly specific activity of fenofibrate toward PPAR␣, whereas fish oil engages additional regulatory pathways to impact numerous biological processes. Our data provide better insight into how fish oil modulates circulating levels of lipids and other metabolites in humans. Moreover, the data may provide clues toward additional potential health benefits of fish oil.
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